Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 2991-2998

  Aeschlimann, J R ^a   Allen, G P ^a   Hershberger, E ^a   Rybak, M J ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GENTAMICIN; GLYCOPEPTIDE; METICILLIN; ORITAVANCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM; BACTERIUM ISOLATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REGRESSION ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; COLONY-FORMING UNITS ASSAY; DRUG THERAPY, COMBINATION; GENTAMICINS; GLYCOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0033743317     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.2991-2998.2000     Document Type: Article

References (34)

1. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus
2. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: Efficacy of ampicillin-sulbactam
3. Development of in-vitro resistance to glycopeptides: Assessment in staphylococci of different species
4. In vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives
5. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
6. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
7. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996
8. Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics
9. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
10. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility
11. Antimicrobial combinations
12. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods
13. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
14. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
15. Pharmacodynamics of vancomycin alone or in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model
16. Comparison of conventional dosing versus continuous infusion vancomycin therapy for patients with suspected or documented gram-positive infections
17. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model
18. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium
19. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus
20. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin
21. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds
22. In-vitro characteristics of glycopeptide resistant strains of Staphylococcus epidermidis isolated from patients on CAPD
23. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin
24. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus
25. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical strains of staphylococci
26. Low-level teicoplanin resistance and heteroresistance to vancomycin
27. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
28. Emergence of vancomycin resistance in Staphylococcus aureus
29. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin
30. In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin
31. Aminoglycosides
32. Vancomycin
33. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study